Answers are grounded in this paper and cite their sources.
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Retifanlimab (Zynyz), 500 mg/20 mL (25 mg/mL), concentrate for solution, IV infusion. Indication: In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: